|
|
ASCO 2012: Dr. Orlowski - Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma
Robert Orlowski, MD
MD Anderson Cancer Center
Houston, Texas, USA
|
|
|
back
button next to the volume control in the
lower right hand corner.
print
related articles